erythropoietic porphyrias (EPP), X-linked protoporphyria
IRONDisc Medicine IncCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Bitopertin in erythropoietic porphyrias (EPP), X-linked protoporphyria . The expected timing is based on the latest available company guidance and may change.
07/30/26:- Type A meeting completed; EAP launched. APOLLO data Q4 2026; CRL response and FDA decision Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.